FDA's Pazdur, sector leaders push for private-public partnership to boost DEI in cancer drug development

Despite recent efforts, major changes are still needed to properly prioritize participant diversity in oncology drug development and meet the White House's reimagined Cancer Moonshot goal of halving the cancer death rate in 25 years, according to several FDA officials and Big Pharma leaders.